Perspective Therapeutics, Inc.

Equities

CATX

US46489V1044

Medical Equipment, Supplies & Distribution

Market Closed - Nyse Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
1.58 ^USD	-1.25%		+5.33%	+293.03%

Apr. 18	Certain Common Stock of Perspective Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 18-APR-2024.	CI
Apr. 18	Certain Warrants of Perspective Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 18-APR-2024.	CI

Perspective Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023

March 28, 2024 at 07:30 am EDT

Perspective Therapeutics, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 46.51 million. Basic loss per share from continuing operations was USD 0.14.

Basic loss per share was USD 0.17.

Latest news about Perspective Therapeutics, Inc.

Certain Common Stock of Perspective Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 18-APR-2024.	Apr. 17	CI
Certain Warrants of Perspective Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 18-APR-2024.	Apr. 17	CI
Certain Stock Options of Perspective Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 18-APR-2024.	Apr. 17	CI
B. Riley Raises Price Target on Perspective Therapeutics to $1.70 From $1.20, Maintains Buy Rating	Apr. 09	MT
Oppenheimer Adjusts Perspective Therapeutics Price Target to $1.50 From $1.20, Maintains Outperform Rating	Apr. 01	MT
Perspective Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
North American Morning Briefing : Markets Steady -2-	Mar. 26	DJ
North American Morning Briefing : Stock Futures -2-	Mar. 19	DJ
Perspective Therapeutics, Bristol-Myers Squibb Collaborate on Melanoma Combination Study	Mar. 18	MT
Transcript : Perspective Therapeutics, Inc. - Analyst/Investor Day	Mar. 18
Perspective Therapeutics, Inc. Announces Clinical Collaboration Agreement with Bristol Myers Squibb to Evaluate [(212)Pb)VMT01 in Combination with Nivolumab in MC1R-Positive Metastatic Melanoma	Mar. 18	CI
Perspective Therapeutics, Inc. announced that it has received $87.409482 million in funding from Lantheus Holdings, Inc. and other investors	Mar. 05	CI
Sector Update: Health Care Stocks Softer in Afternoon Trading	Mar. 04	MT
Perspective Therapeutics to Raise $87.4 Million in Private Placement	Mar. 04	MT
Perspective Therapeutics, Inc. completed the acquisition of Radiopharmaceutical Manufacturing Facility in Somerset, New Jersey from Progenics Pharmaceuticals, Inc.	Feb. 29	CI
Perspective Therapeutics, Inc. Introduces Pre-Targeting Theranostic Technology Platform	Feb. 01	CI
B. Riley Starts Perspective Therapeutics With Buy Rating, $1.20 Price Target; Says Well-Positioned to Break Out of Biotech Pack	Jan. 26	MT
Perspective Therapeutics Closes $89.8 Million Public Offering, Concurrent Private Placement	Jan. 22	MT
Perspective Therapeutics to Raise Nearly $81 Million via Public Offering, Private Placement	Jan. 18	MT
Sector Update: Health Care Stocks Mixed Premarket Thursday	Jan. 18	MT
Perspective Therapeutics, Inc. announced that it expects to receive $20.8 million in funding	Jan. 17	CI
Perspective Therapeutics Launching Public Offering	Jan. 17	MT
Perspective Therapeutics, Inc. Commences Recruitment for Second Dose Escalation Cohorts in Clinical Studies of Two Lead Programs	Jan. 17	CI
Lantheus Holdings Signs Share Purchase, Licensing Deals With Perspective Therapeutics	Jan. 09	MT
Perspective Therapeutics, Inc. Enters into Strategic Agreements with Lantheus Including Equity Investment, Co-Development Options, and Expansion of Manufacturing Capability	Jan. 09	CI

Chart Perspective Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Perspective Therapeutics, Inc. is a precision oncology company developing alpha-particle therapies and complementary diagnostic imaging agents. The Company is focused on the advancement of cancer treatments using radiation, radiopharmaceuticals, and imaging technologies, so its targeted medical doses are delivered directly to the tumor site. The Companyâs core product is its Cesium-131 sealed source brachytherapy seed. These seeds can be inserted individually or in combination into various locations in the body. The Company also sells seeds in strands to keep them from individually moving. The Companyâs segments are Brachytherapy and Drug Operations. Brachytherapy includes sales and manufacturing of Cesium-131 brachytherapy seeds, including research and development of new applications for the seeds. Drug Operations includes research and development and clinical operations related to the use of Lead-203 and Lead-212 as a diagnostic and a therapeutic drug.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-05-13 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.58 USD

Average target price

1.6 USD

Spread / Average Target

+1.27%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
PERSPECTIVE THERAPEUTICS, INC.	+293.03%	927M
ABBOTT LABORATORIES	-2.31%	187B
MEDTRONIC PLC	-3.20%	106B
BECTON, DICKINSON AND COMPANY	-5.04%	66.9B
DEXCOM, INC.	+0.20%	49.45B
CENCORA, INC.	+17.29%	48B
HOYA CORPORATION	+4.06%	40.84B
METTLER-TOLEDO INTERNATIONAL, INC.	+2.07%	26.48B
WEST PHARMACEUTICAL SERVICES, INC.	+2.36%	26.25B
TERUMO CORPORATION	+12.96%	24.62B

Other Medical Equipment, Supplies & Distribution